Siemens Healthineers Adds Pathway for Lung Cancer to its AI-based Clinical Decision Support Software

Siemens HealthineersSiemens Healthineers presents its second pathway for its AI-Pathway Companion(1) at the Healthcare Information and Management Systems Society Global Health Conference 2021 (HIMSS 21). This new pathway is focused on non-small cell lung cancer, supporting personalized and standardized decision-making along the whole treatment process(2). The AI-Pathway Companion Lung Cancer(3) assists multidisciplinary teams (MDT) by facilitating patient management and case reviews in a single dashboard, providing quality checks on data completeness, and enabling the documentation of clinically relevant patient-specific notations. "During lung MDT discussion, it frequently becomes apparent that a key diagnostic report or other crucial information is not yet available. These patients have to be discussed again in the next meeting. This wastes time and effort for all physicians involved in the MDT. A digital assistant, which ensures that the right set of information is available, would substantially increase efficiency," says Prof. Mathias Prokop, Head of the department Radiology, Nuclear Medicine and Anatomy, Radboud University Nijmegen(4).

AI-Pathway Companion

Siemens Healthineers adds the pathway for lung cancer for its AI-Pathway Companion to the already existing CE-marked pathway for prostate cancer. The software is designed to help in advanced oncology care by integrating contextualized data along the patient pathway. Utilizing the full pathway with all available data(2), healthcare professionals can optimize the treatment for the individual patient and adherence to evidence-based standards of care is easier to accomplish(5). This transparency also helps collaboration across departments and cancer boards. Everyone involved always has the full picture and can contribute to the treatment discussion with their specific knowledge. "The introduction of the AI-Pathway Companion Lung Cancer demonstrates our continued commitment to supporting healthcare providers in their transformation to value-based healthcare. With the AI-Pathway Companion solution, we are presenting a next-gen clinical decision support system; we want to continue trail blazing in this market by partnering with key customers on future innovation," says Wido Menhardt, Head of Digital Health at Siemens Healthineers.

Through ongoing development and refinement of data interfaces, Siemens Healthineers aims to increase the number of disease parameters captured throughout the clinical pathway, thereby expanding the relevant data points with the goal of advancing cancer care. The company looks forward to partnering with even more healthcare institutions on optimizing the AI-Pathway Companion solution to their routine clinical practice and preferred lung cancer workflow.

About Siemens Healthineers AG

Siemens Healthineers AG (listed in Frankfurt, Germany: SHL) is shaping the future of healthcare. As a leading medical technology company headquartered in Erlangen, Germany, Siemens Healthineers enables healthcare providers worldwide through its regional companies to increase value by empowering them on their journey towards expanding precision medicine, transforming care delivery, improving the patient experience, and digitalizing healthcare. Siemens Healthineers is continuously developing its product and service portfolio, with AI-supported applications and digital offerings that play an increasingly important role in the next generation of medical technology. These new applications will enhance the company's foundation in in-vitro diagnostics, image-guided therapy, in-vivo diagnostics, and innovative cancer care. Siemens Healthineers also provides a range of services and solutions to enhance healthcare providers’ ability to provide high-quality, efficient care to patients. In fiscal 2020, which ended on September 30, 2020, Siemens Healthineers generated revenue of €14.5 billion and adjusted EBIT of €2.2 billion. Following the acquisition of Varian Medical Systems, Inc. the company has approximately 66,000 employees worldwide.

1. AI-Pathway Companion consists of several health products and medical devices in their own right, and products under development. AI-Pathway Companion is not commercially available in all countries. Their future availability cannot be guaranteed.
2. All data is available as required per guideline. Feature dependent on quality of input data.
3. AI-Pathway Companion Lung Cancer VA10A supports Singlenprimary tumor. AI-Pathway Companion Lung Cancer VA10A supports Nonsmallncell Lung cancer cases only.
4. Dr. Mathias Prokop is employed by an institution that receives financial support from Siemens Healthineers for collaborations.
5. All data is available as required per guideline. Feature dependent on quality of input data. AI-Pathway Companion Lung Cancer VA10A supports NCCN guidelines. Customer shall ensure that guidelines are applicable and appropriate as per the local site policies and procedures and access to procedures.

Most Popular Now

AI Identifies Anti-Aging Drug Candidates…

A new publication in the May issue of Nature Aging by researchers from Integrated Biosciences, a biotechnology company combining synthetic biology and machine learning to target aging, demonstrates the power...

AI could Improve Heart Attack Diagnosis …

An algorithm developed using artificial intelligence (AI) could soon be used by doctors to diagnose heart attacks with better speed and accuracy than ever before, according to new research from...

AI Predicts Future Pancreatic Cancer

An artificial intelligence (AI) tool has successfully identified people at the highest risk for pancreatic cancer up to three years before diagnosis using solely the patients’ medical records, according to...

New Algorithm can Predict Diabetic Kidne…

Researchers from Sanford Burnham Prebys and the Chinese University of Hong Kong have developed a computational approach to predict whether a person with type 2 diabetes will develop kidney disease...

AI Voice Coach Shows Promise in Depressi…

Artificial intelligence (AI) could be a useful tool in mental health treatment, according to the results of a new pilot study led by University of Illinois Chicago researchers. The study...

AI could Run a Million Microbial Experim…

An artificial intelligence (AI) system enables robots to conduct autonomous scientific experiments - as many as 10,000 per day - potentially driving a drastic leap forward in the pace of...

Scientists develop AI tool to predict Pa…

Scientists from UNSW Sydney with collaborators at Boston University have developed a tool that shows early promise in detecting Parkinson’s disease years before the first symptoms start appearing. In research published...

Better than Humans: AI in Intensive Care…

In the future, artificial intelligence (AI) will play an important role in medicine. In diagnostics, successful tests have already been performed: for example, the computer can learn to categorise images...

Could Online Gaming Social Networks Have…

For millions of Americans playing some type of video game is a daily occurrence. Games can be a welcome form of entertainment and relaxation for many, and the internet can...

ChatGPT Passes Radiology Board Exam

The latest version of ChatGPT passed a radiology board-style exam, highlighting the potential of large language models but also revealing limitations that hinder reliability, according to two new research studies...

Siemens Healthineers Opens State-of-the-…

Siemens Healthineers has opened its new Education & Development Center (EDC) in Erlangen. The open-plan building offers space for the currently 240 trainees and integrated degree program participants in Erlangen...

Siemens Healthineers Invests 80 Million …

Siemens Healthineers is building a new factory in Forchheim for the cultivation of crystals for semiconductor production. The total investment amounts to 80 million euros. The new factory is expected...